Literature DB >> 21793098

The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals.

Mariley Pérez García1, Albert Figueras.   

Abstract

BACKGROUND: Underreporting suspected adverse drug reactions (ADRs) is one of the main problems that face the pharmacovigilance (PhV) systems based on yellow card schemes.
OBJECTIVES: To measure the knowledge level on the suspected ADR voluntary reporting system among physicians and pharmacists in Venezuela and to study its relationship with different variables.
METHODS: A population-based, anonymous, and self-administered questionnaire was addressed to health professionals along the national territory of Venezuela. An algorithm was developed to classify the knowledge level on the voluntary reporting system.
RESULTS: Taken as a whole, the level of knowledge on the voluntary reporting system was "poor." Among the 515 participant physicians, 62.3% (95%CI = 58.0-66.5%) had a "poor" level of knowledge; PhV was associated with "control" of medicines use, and only 24.7% had ever reported a suspected ADR. "Medical specialty" was the only variable that showed a relationship with the knowledge level (p = 0.0041). Among the 78 participant pharmacists, 66.7% had a "poor" knowledge level (95%CI = 55.1-76.9%).
CONCLUSIONS: The knowledge level on the voluntary reporting system among physicians and pharmacists in Venezuela is poor. These results strengthen the hypothesis that being unaware of the adverse effects of medicines and not knowing the existence of a PhV system is a major cause of underreporting. A careful study of the actual knowledge of PhV could be the basis to set up interventions specifically designed to overcome misleading concepts and to improve the reporting rate at a national level.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21793098     DOI: 10.1002/pds.2193

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  23 in total

1.  A Review of Pharmacovigilance.

Authors:  J E Campbell; M Gossell-Williams; M G Lee
Journal:  West Indian Med J       Date:  2015-03-05       Impact factor: 0.171

2.  Adverse drug event reporting: awareness is not enough.

Authors:  Joyce A Generali
Journal:  Hosp Pharm       Date:  2014-02

3.  First Indian study evaluating role of biochemical investigations and diagnostic tools in detection of adverse drug reactions.

Authors:  Vishal R Tandon; Vijay Khajuria; Kapila Raina; Vivek Mahajan; Aman Sharma; Zahid Gillani
Journal:  J Clin Diagn Res       Date:  2014-09-20

4.  Knowledge and Barriers Among Physicians Toward Adverse Drug Reaction Reporting at a Tertiary Care Hospital in Saudi Arabia.

Authors:  Dalal Abdulrazaq Al-Abdulkarim; Hisham S Aljadhey; Mansour A Mahmoud; Gregory A Poff; Mohamed Azmi Hassali; Sheraz Ali
Journal:  Hosp Pharm       Date:  2020-03-04

5.  Teaching Pharmacovigilance to Undergraduate Students: Our Experience in Poor-Resource Setting.

Authors:  Mohammed Alshakka; Wafa Badullah; Abdullah Al-Dhuraibi; Sara Alshagga; Mohamed Izham Mohamed Ibrahim
Journal:  J Pharm Bioallied Sci       Date:  2022-05-19

6.  Using computable knowledge mined from the literature to elucidate confounders for EHR-based pharmacovigilance.

Authors:  Scott A Malec; Peng Wei; Elmer V Bernstam; Richard D Boyce; Trevor Cohen
Journal:  J Biomed Inform       Date:  2021-03-11       Impact factor: 6.317

7.  Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.

Authors:  Vishal R Tandon; Vivek Mahajan; Vijay Khajuria; Zahid Gillani
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

8.  Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study.

Authors:  Adriana Parrella; Annette Braunack-Mayer; Michael Gold; Helen Marshall; Peter Baghurst
Journal:  BMC Health Serv Res       Date:  2013-08-15       Impact factor: 2.655

9.  Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).

Authors:  C Mathieu; A H Barnett; H Brath; I Conget; J J de Castro; R Göke; E Márquez Rodriguez; P M Nilsson; E Pagkalos; A Penfornis; N C Schaper; S K Wangnoo; W Kothny; G Bader
Journal:  Int J Clin Pract       Date:  2013-08-21       Impact factor: 2.503

10.  Predictive Factors of Spontaneous Reporting of Adverse Drug Reactions among Community Pharmacists.

Authors:  Yun Mi Yu; Euni Lee; Bon Sun Koo; Kyeong Hye Jeong; Kyung Hee Choi; Lee Kyung Kang; Mo Se Lee; Kwang Hoon Choi; Jung Mi Oh; Wan Gyoon Shin
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.